Sutimlimab Biosimilar – Research Grade
ichorbio’s sutimlimab biosimilar is for Research Use Only (RUO) and not for therapeutic use.
ichorbio’s RUO sutimlimab biosimilar is available in the following sizes:
5mg, 10mg, 20mg, 50mg
ichorbio regularly manufactures bulk multi-gram amounts of this biosimilar – please contact us for pricing.
C1s in classical complement pathway
Detects human C1s. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody sutimlimab.
This recombinant protein was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
RUO sutimlimab biosimilar is a humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system. By blocking C1s, sutimlimab inhibits the activation of the classical complement pathway with the goal of halting C1-activated hemolysis in cold agglutinin disease to prevent the abnormal destruction of healthy red blood cells. By selectively inhibiting the classical pathway upstream at C1s, sutimlimab does not inhibit the lectin and alternative complement pathways..
1.0 – 5.0 mg/ml
Sterile, preservative-free, solution in PBS. BSA and Azide free.
>95% by SDS-PAGE and HPLC
≤ 1.0 EU/mg as determined by the LAL method
Sutimlimab Biosimilar – Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Each investigator should determine their own optimal working dilution for specific applications.
ichorbio’s sutimlimab biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.